Reduction of dopamine D2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
R-ketamine appears to be a potent, long-lasting and safer antidepressant, relative to esketamine (S-ketamine), since it might be free of psychotomimetic side effects. Using [ 11 C]raclopride and positron emission tomography (PET), we investigated whether esketamine and R-ketamine can affect dopamine D 2/3 receptor binding in the conscious monkey brain. A single infusion of esketamine (0.5 mg/kg), but not R-ketamine (0.5 mg/kg), caused a reduction of binding availability of dopamine D 2/3 receptor in the monkey striatum. This study suggests that unlike to R-ketamine, esketamine can cause dopamine release in the striatum, and that its release might be associated with psychotomimetic effects of esketamine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Effect of esketamine and R-ketamine on the BPND of [11C]raclopride to dopamine D2/3 receptors in the striatum of conscious monkeys. a Representative photomicrographs of typical MRI and parametric PET images of [11C]raclopride to dopamine D2/3 receptors from vehicle (saline)-treated, esketamine (0.5 mg/kg, 40-min)-treated and R-ketamine (0.5 mg/kg, 40-min)-treated monkeys. PET images from 61 to 91 min were obtained. Color bar indicates a level of the non-displaceable binding potential (BPND) of [11C]raclopride. b The non-displaceable binding potential BPND of [11C]raclopride in the striatum. The data show the mean ± S.E.M. (n = 4). **P < 0.01 compared with vehicle (saline)-treated condition](https://figures.cochat.ai/paper-figures/20e6477afd9f436cbcaea3029ca73a7b/reduction-of-dopamine-d2-3-receptor-binding-in-the-striatum-after-a-single-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In animal studies, R-ketamine has been reported to have a rapid onset of antidepressant effects and a better side-effect profile than esketamine34–41”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [40]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands
Innis, R. B., Cunningham, V. J., Delforge, J., Fujita, M., Gjedde, A., Gunn, R. N., Holden, J., Houle, S., Huang, S.-C., Ichise, M., et al. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600493 · Cited by 1,955
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Self-citationKetamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Domino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520
Singh, J. B., Fedgchin, M., Daly, E., Xi, L., Melman, C., De Bruecker, G., Tadic, A., Sienaert, P., Wiegand, F., Manji, H., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.10.018 · Cited by 466
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Self-citationA high resolution animal PET scanner using compact PS-PMT detectors
Watanabe, M., Okada, H., Shimizu, K., Omura, T., Yoshikawa, E., Kosugi, T., Mori, S., & Yamashita, T. (1997) · IEEE Transactions on Nuclear Science · doi:10.1109/23.597001 · Cited by 241
Vollenweider, F. X., Vontobel, P., Øye, I., Hell, D., & Leenders, K. L. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00031-x · Cited by 223
Tsukada, H., Harada, N., Nishiyama, S., Ohba, H., & Kakiuchi, T. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-18-07067.2000 · Cited by 99
Self-citationYamamoto, S., Ohba, H., Nishiyama, S., Harada, N., Kakiuchi, T., Tsukada, H., & Domino, E. F. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.176 · Cited by 76
Self-citationRapid antidepressant effects and abuse liability of ketamine
Yang, C., & Hashimoto, K. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3543-0 · Cited by 43
Self-citationHashimoto, K. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.1.72 · Cited by 42
Self-citationSuzuki, T., Aoki, T., Kato, H., Yamazaki, M., & Misawa, M. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00762-1 · Cited by 36
Cited by
Hashimoto, K. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12902 · Cited by 335
“5 mg/kg for 40-min).(106) This positron emission tomography study suggests that (S)-ketamine-induced marked dopamine release from the presynaptic terminal may contribute to acute side-effects (i.”
BackgroundSelf-citationPharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability
Bonaventura, J., Lam, S., Carlton, M., Boehm, M. A., Gomez, J. L., Solís, O., Sánchez-Soto, M., Morris, P. J., Fredriksson, I., Thomas, C. J., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01093-2 · Cited by 271
“, increased dopamine tone) after intravenous injection of (S)-ketamine but not to (R)-ketamine [59].”
BackgroundIntravenous arketamine for treatment-resistant depression: open-label pilot study
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., et al. (2021) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01110-5 · Cited by 257
“Another important aspect is the apparent lower incidence of psychotomimetic effects with arketamine than with other forms, and it might be explained by its lower potential to produce dopamine release and reduction of parvalbumin-positive neurons when compared with esketamine as demonstrated in animal studies [16, 31].”
ResultAntidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Self-citationYang, C., Ren, Q., Qu, Y., Zhang, J.-C., Ma, M., Dong, C., & Hashimoto, K. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.016 · Cited by 250
Self-citation
Metadata
- Authors
- Hashimoto, K., Kakiuchi, T., Ohba, H., Nishiyama, S., & Tsukada, H.
- Affiliations
- Chiba University (JP)
- Hamamatsu Photonics (Japan) (JP)
- Corresponding author
- Hashimoto, Kenji
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2016-04-18
- Volume
- 267
- Issue
- 2
- Pages
- 173-176
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- PMC
- PMC5323469
- OpenAlex
- W2337679024
- Cited by
- 127
- References
- 19
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 13 · 2023: 10 · 2022: 13 · 2021: 14 · 2020: 19 · 2019: 16 · 2018: 12 · 2017: 11 · 2016: 6
- FWCI
- 12.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology (24116006)
- Chiba University
- National Institutes of Health
- Japan Society for the Promotion of Science (24116006)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- esketamine, (R)-ketamine, dopamine D2/D3 receptors, striatum, psychotomimetic effects, dopamine release, antidepressants, conscious monkeys
- MeSH terms
- Animals, Antidepressive Agents, Ketamine, Macaca mulatta, Male, Neostriatum, Receptors, Dopamine D2, Positron-Emission Tomography, Receptors, Dopamine D3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.